TRCT
BIB icon

Tower Research Capital (TRC)’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80K Buy
982
+44
+5% +$3.65K ﹤0.01% 2362
2025
Q4 		$74.8K Buy
938
+380
+68% +$28.1K ﹤0.01% 2147
2025
Q3 		$33.2K Sell
558
-2,042
-79% -$110K ﹤0.01% 2855
2025
Q2 		$119K Sell
2,600
-1,836
-41% -$80.8K ﹤0.01% 2239
2025
Q1 		$214K Sell
4,436
-890
-17% -$47.7K 0.01% 1327
2024
Q4 		$270K Buy
5,326
+1,266
+31% +$75K 0.01% 1497
2024
Q3 		$259K Sell
4,060
-8,280
-67% -$535K 0.01% 1380
2024
Q2 		$731K Buy
12,340
+12,330
+123,300% +$682K 0.01% 1013
2024
Q1 		$575 Sell
10
-1,432
-99% -$83K ﹤0.01% 5437
2023
Q4 		$82.3K Sell
1,442
-5,015
-78% -$235K ﹤0.01% 2782
2023
Q3 		$310K Buy
6,457
+5,422
+524% +$279K 0.01% 1162
2023
Q2 		$53.8K Sell
1,035
-2,616
-72% -$144K ﹤0.01% 2526
2023
Q1 		$198K Sell
3,651
-8,905
-71% -$503K 0.01% 1377
2022
Q4 		$725K Buy
12,556
+12,278
+4,417% +$691K 0.03% 511
2022
Q3 		$13K Sell
278
-13,799
-98% -$735K ﹤0.01% 4256
2022
Q2 		$681K Buy
14,077
+14,062
+93,747% +$715K 0.02% 939
2022
Q1 		$1K Sell
15
-10,738
-100% -$659K ﹤0.01% 5747
2021
Q4 		$872K Sell
10,753
-1,828
-15% -$157K 0.02% 765
2021
Q3 		$1.19M Sell
12,581
-6,794
-35% -$687K 0.03% 454
2021
Q2 		$1.91M Sell
19,375
-830
-4% -$72.4K 0.05% 327
2021
Q1 		$1.69M Buy
+20,205
New +$1.91M 0.03% 543
2020
Q4 		– Sell
-49,533
Closed -$3.47M – 5128
2020
Q3 		$3.47M Buy
49,533
+49,333
+24,667% +$3.5M 0.04% 155
2020
Q2 		$15K Sell
200
-680
-77% -$43.4K ﹤0.01% 3810
2020
Q1 		$41K Sell
880
-20,453
-96% -$1.14M ﹤0.01% 1379
2019
Q4 		$1.32M Buy
21,333
+16,568
+348% +$884K 0.11% 85
2019
Q3 		$202K Sell
4,765
-59,730
-93% -$2.83M 0.01% 999
2019
Q2 		$3.34M Buy
64,495
+54,792
+565% +$2.73M 0.23% 56
2019
Q1 		$539K Sell
9,703
-16,618
-63% -$895K 0.03% 556
2018
Q4 		$1.11M Sell
26,321
-772
-3% -$40.3K 0.08% 243
2018
Q3 		$1.89M Buy
27,093
+16,397
+153% +$1.07M 0.14% 112
2018
Q2 		$612K Buy
10,696
+10,535
+6,543% +$574K 0.03% 546
2018
Q1 		$9K Sell
161
-47,865
-100% -$2.87M ﹤0.01% 2490
2017
Q4 		$2.69M Buy
48,026
+47,961
+73,786% +$2.71M 0.35% 46
2017
Q3 		$4K Sell
65
-26,996
-100% -$1.54M ﹤0.01% 3372
2017
Q2 		$1.45M Buy
27,061
+19,287
+248% +$941K 0.16% 108
2017
Q1 		$375K Sell
7,774
-14,731
-65% -$685K 0.04% 178
2016
Q4 		$898K Sell
22,505
-28,667
-56% -$1.22M 0.1% 223
2016
Q3 		$2.48M Sell
51,172
-58,661
-53% -$2.79M 0.25% 44
2016
Q2 		$4.27M Buy
109,833
+17,031
+18% +$734K 0.41% 39
2016
Q1 		$3.79M Buy
92,802
+66,221
+249% +$2.93M 0.56% 29
2015
Q4 		$1.9M Buy
26,581
+25,244
+1,888% +$1.69M 0.31% 43
2015
Q3 		$78K Sell
1,337
-7,003
-84% -$597K 0.01% 715
2015
Q2 		$754K Sell
8,340
-15,788
-65% -$1.36M 0.07% 110
2015
Q1 		$1.91M Sell
24,128
-26,666
-52% -$1.98M 0.24% 59
2014
Q4 		$3.19M Buy
50,794
+13,762
+37% +$807K 0.31% 50
2014
Q3 		$1.93M Sell
37,032
-13,118
-26% -$636K 0.22% 88
2014
Q2 		$2.33M Buy
+50,150
New +$1.98M 0.3% 40

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return

Tower Research Capital (TRC)'s BIB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 4.7% in Q1 2026, buying an estimated $3.65K and bringing the position to 982 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Tower Research Capital (TRC) first reported a position in BIB in Q2 2014 and has held it in 47 quarters since. The position peaked at $4.27M in Q2 2016. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Tower Research Capital (TRC) held 982 shares of ProShares Ultra NASDAQ Biotechnology worth $80K as of Q1 2026.
  • Tower Research Capital (TRC) bought 44 ProShares Ultra NASDAQ Biotechnology shares in Q1 2026, an estimated $3.65K.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2362 holding.
  • Tower Research Capital (TRC) first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and has held it in 47 quarters since.
  • Tower Research Capital (TRC)'s ProShares Ultra NASDAQ Biotechnology position peaked at $4.27M in Q2 2016.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.